Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 1.00 |
| ▸ | THRB | P10828 | 11/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 10/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.71 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.71 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.71 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.71 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.71 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.71 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.71 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.71 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.71 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740016 | 1.00 | TGFBR1 (1.00) | TGFBR1THRBMAPK14GAKRIPK2 | |
| SCHEMBL409533 | 0.92 | TGFBR1 (0.85) | TGFBR1THRBMAPK14GAKRIPK2 | |
| SCHEMBL12922146 | 0.89 | TGFBR1 (0.82) | TGFBR1THRBMAPK14GAKRIPK2 | |
| SCHEMBL413994 | 0.88 | TGFBR1 (0.78) | TGFBR1THRBMAPK14GAKRIPK2 | |
| SCHEMBL409351 | 0.88 | TGFBR1 (0.78) | TGFBR1THRBMAPK14GAKRIPK2 | |
| SCHEMBL413726 | 0.88 | TGFBR1 (0.78) | TGFBR1THRBMAPK14GAKRIPK2 | |
| SCHEMBL5232917 | 0.88 | TGFBR1 (0.78) | TGFBR1THRBMAPK14GAKRIPK2 | |
| SCHEMBL23852042 | 0.87 | TGFBR1 (0.80) | TGFBR1THRBMAPK14GAKRIPK2 | |
| SCHEMBL1027982 | 0.87 | TGFBR1 (0.80) | TGFBR1THRBMAPK14GAKRIPK2 | |
| SCHEMBL373523 | 0.87 | TGFBR1 (1.00) | TGFBR1THRBMAPK14GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | claimed |
| CN-1269820-C | Novel pyrrole derivatives as medicaments | LILLY CO ELI (US) | 2006-08-16 | — | — | CN | claimed |
| CN-1511157-A | Novel pyrrole derivatives as medicaments | — | 2004-07-07 | — | — | CN | claimed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | claimed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | claimed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | claimed |
| US-11987558-B1 | ALK5 inhibitors and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240053327-A1 | NEURAL STEM CELL-INDUCED DIFFERENTIAL MEDIUM AND INDUCTION DIFFERENTIATION METHOD | IREGENE THERAPEUTICS LTD (CN) | 2024-02-15 | — | — | US | disclosed |
| US-20230321076-A1 | APPLICATION OF TGF-B INHIBITOR IN INDUCING NEURAL STEM CELLS AND ORGANOID FORMATION | IREGENE THERAPEUTICS LTD (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | SYNTHIS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| CN-1951939-A | Novel pyrrole derivatives as pharmaceutical agents | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| CN-1269820-C | Novel pyrrole derivatives as medicaments | LILLY CO ELI (US) | 2006-08-16 | — | — | CN | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| CN-1511157-A | Novel pyrrole derivatives as medicaments | — | 2004-07-07 | — | — | CN | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987558-B1 | ALK5 inhibitors and their uses | ALK, ALKBH3, ALKBH5 | TGFBR1 106/4885THRB 892/4885MAPK14 1923/4885 |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885THRB 1981/4885MAPK14 2643/4885 |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | ALK, ALKBH5, ALKBH3 | TGFBR1 75/4885THRB 2718/4885MAPK14 1174/4885 |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885THRB 1981/4885MAPK14 2643/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885THRB 500/4885MAPK14 546/4885 |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885THRB 1981/4885MAPK14 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.